Kurz gefasst
Editorial in der Zeitschrift Science, 2024. Verfasst von Rayne H Rouce und 1 weiteren Autor:innen. Beteiligte Einrichtung: Rayne H. Rouce is an associate professor at the Center for Cell and Gene Therapy, Dan L. Duncan Comprehensive Cancer Center, Texas Children's Hospita…. Hauptthemen laut MEDLINE: Cell- and Tissue-Based Therapy, Genetic Therapy, Health Services Accessibility. Die Arbeit wurde bisher 23-mal zitiert (Crossref).
Abstract (Originalsprache)
Patients with devastating illnesses demonstrate incredible courage in battling their disease. Innovative cell and gene therapies (CGTs), built on decades of research, are changing the lives of those who suffer from conditions ranging from cancer to sickle cell disease to neurologic diseases. Although hailed for their promise and recognized for benefits that will exceed the costs, the high prices of CGTs ($300 thousand to $4 million per dose) leave these therapies out of reach for many. This accessibility problem will only be solved if academia, industry, investors, funders, regulators, and advocacy groups work together to put CGT breakthroughs in the hands of all who stand to benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Rayne H. Rouce is an associate professor at the Center for Cell and Gene Therapy, Dan L. Duncan Comprehensive Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
- Matthew H. Porteus is a professor in the Department of Pediatrics and the Center for Definitive and Curative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Zitieren
APA
Rouce, R. H., & Porteus, M. H. (2024). Cell and gene therapy accessibility. Science. https://doi.org/10.1126/science.ads0252
Vancouver
Rouce RH, Porteus MH. Cell and gene therapy accessibility. Science. 2024. doi:10.1126/science.ads0252
BibTeX
@article{Rouce2024,
author = {Rouce, Rayne H and Porteus, Matthew H},
title = {Cell and gene therapy accessibility},
journal = {Science},
year = {2024},
doi = {10.1126/science.ads0252}
}
EUVIMED